top of page

Pulmonary disease

  • There are 6 million people with asthma worldwide, and 5% of patients with asthma develop severe asthma as the disease worsens.

  • Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with a poor prognosis. The patients have a 5-year survival rate of less than 50% and a 10-year survival rate of 15% after diagnosis. IPF affects approximately 3 million people worldwide, and its incidence rate is also increasing.

  • A curative treatment for IPF has not yet been developed, and available treatments only delay the progression of the disease. The only method to lower the mortality rate is lung transplantation, which is performed in patients aged < 65 years without other underlying diseases.

  • Intencell® is expected to be the only therapeutic agent for idiopathic pulmonary fibrosis as it has excellent anti-inflammatory effects and is expected to be effective in the regeneration of fibrotic tissues.

(Reference: National Institutes of Health)

  • In a preclinical study, IntenCell®-derived exosomes (IntenExso®) exhibited anti-inflammatory effects, alveolar epithelial cell regeneration, and fibrolysis.

  • IntenCell® is expected to be a novel highly effective treatment for pulmonary diseases because of its excellent properties of anti-inflammation and fibrosis-damaged tissue regeneration.

bottom of page